
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
China SXT Pharmaceuticals Inc (SXTC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SXTC (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -23.39% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.57M USD | Price to earnings Ratio 0.01 | 1Y Target Price - |
Price to earnings Ratio 0.01 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.1 | 52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 |
52 Weeks Range 0.95 - 11.92 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 124.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 318.69% | Operating Margin (TTM) -76.95% |
Management Effectiveness
Return on Assets (TTM) 18.15% | Return on Equity (TTM) 57.63% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value 190144853 | Price to Sales(TTM) 109.75 |
Enterprise Value 190144853 | Price to Sales(TTM) 109.75 | ||
Enterprise Value to Revenue 104.57 | Enterprise Value to EBITDA 29.92 | Shares Outstanding 116028000 | Shares Floating 488309 |
Shares Outstanding 116028000 | Shares Floating 488309 | ||
Percent Insiders 0.02 | Percent Institutions 0.01 |
Upturn AI SWOT
China SXT Pharmaceuticals Inc
Company Overview
History and Background
China SXT Pharmaceuticals Inc. was founded with a focus on traditional Chinese medicine (TCM) products. It has grown through product development and market expansion within China.
Core Business Areas
- TCM Granules: Development, production, and sale of TCM granules, used for individualized prescriptions by doctors.
- TCM Products: Manufacture and distribution of over-the-counter TCM products for various health conditions.
Leadership and Structure
Information regarding China SXT Pharmaceutical Inc's leadership team and organizational structure is not readily available in detail within publicly accessible financial information sources.
Top Products and Market Share
Key Offerings
- TCM Granules: Individualized TCM granule prescriptions. Market share data is unavailable. Competitors include other TCM manufacturers and pharmacies offering TCM services within China.
- Over-the-Counter TCM Products: Various TCM products for common ailments. Market share data is unavailable. Competitors include large pharmaceutical companies and smaller TCM manufacturers in China.
Market Dynamics
Industry Overview
The TCM industry in China is large and growing, driven by government support and increasing consumer demand. There is considerable competition.
Positioning
China SXT Pharmaceuticals Inc is positioned as a TCM product and granule manufacturer, competing with numerous other TCM companies. Its competitive advantage, if any, is not clear from readily available information.
Total Addressable Market (TAM)
The TAM for TCM in China is significant, estimated to be in the billions of dollars annually. China SXT Pharmaceuticals Inc.'s position within the TAM is dependent on its market share which is not available publicly.
Upturn SWOT Analysis
Strengths
- Established presence in the Chinese TCM market
- Focus on TCM granules
- Potential for growth in the expanding TCM market
Weaknesses
- Limited market share data available
- Lack of detailed financial information
- High competition in the TCM market
Opportunities
- Expand product offerings
- Increase market share within China
- Explore international markets
Threats
- Regulatory changes in the Chinese pharmaceutical industry
- Competition from larger pharmaceutical companies
- Fluctuations in raw material costs
Competitors and Market Share
Key Competitors
- CRBP
- JAZZ
- VRX
Competitive Landscape
Compared to competitors, China SXT Pharmaceuticals Inc. may have a specialized focus on TCM granules, but lacks the scale and diversification of larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are difficult to assess without readily available financial data following delisting.
Future Projections: Future growth projections are unavailable without analyst estimates. Which are hard to come by since it is a smaller company and recently delisted
Recent Initiatives: Recent strategic initiatives are not readily available from public sources.
Summary
China SXT Pharmaceuticals Inc. operates in the growing TCM market in China and has a targeted approach with its TCM granules. The lack of publicly available financial data makes it difficult to assess its current financial strength and future prospects accurately. Competition within the TCM market is intense, requiring China SXT to differentiate itself. Understanding the regulatory environment and adapting to market dynamics is vital for the company's success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Financial News Outlets
- Industry Reports
- Company Press Releases
Disclaimers:
The analysis is based on publicly available information and may not be completely accurate or up-to-date. Market share and financial data are estimates and should be treated with caution.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China SXT Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-01-04 | Chairman of the Board & Co-CEO Mr. Feng Zhou | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 75 | Website https://www.sxtchina.com |
Full time employees 75 | Website https://www.sxtchina.com |
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.